LYMPHOMA Archives - Healthcare Communications Network

American Society of HematologyActivity of mRNA COVID-19 Vaccines in Patients with Lymphoid Malignancies

Publication: Blood AdvancesDesign: Multicohort study, 46 total patients (23 patients with lymphoma/CLL and 23 healthy adults, all of whom received the mRNA vaccine)Conclusion: Patients with lymphoid malignancies, and most dramatically those with recent anti-CD20 monoclonal antibody treatment, have reduced humoral responses to mRNA COVID-19 vaccines as compared with healthy control. Related Article: Efficacy of the […]

American Society of HematologyClonal Hematopoiesis in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Source: Blood AdvancesKey Points: In a cohort of 154 patients with NHL or MM receiving CAR T-cells, clonal hematopoiesis of indeterminate potential (CHIP) was present in 48%. Although associated with worse prognosis in these patients receiving autologous transplantation, no such association was seen in these patients receiving CAR T. Instead, the authors saw increased rates […]

Wolters KluwerFDA Actions and Updates

From the pages of Oncology Times comes the latest approvals, designations, and new indications from the U.S. Food and Drug Administration (FDA) for oncology drugs. Stories include new approvals in multiple myeloma, esophageal or gastroesophageal junction (GEJ) carcinoma, non-small cell lung cancer (NSCLC), anaplastic lymphoma, and more.

American Society of HematologyFDA Accepts sNDA for Zanubrutinib in Waldenström Macroglobulinemia

More good news for zanubrutinib, which received accelerated approval in November 2019 in the US for the treatment of mantle cell lymphoma (MCL) in adult patients who have undergone at least one prior therapy. The supplemental new drug application (sNDA) was submitted by the drug’s manufacturer, BeiGene, based on data from the global phase III […]

M3Lymphoma is Largely Gone After COVID-19 Infection

This fascinating case of a 61-year-old male in the UK is the only report so far regarding COVID-19 induced cancer remission. Ridden with stage 3 Hodgkin lymphoma, the COVID-19 infected patient was hospitalized for 11 days but did not receive any cancer treatments. Four months later, PET-CT scans show the lymphoma largely gone. How did […]

American Society of Clinical OncologyDiffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm

How can oncologists successfully implement precision medicine strategies in diffuse large B-cell lymphoma (DLBCL)? In this review, the authors describe the recently proposed genomic categories of DLBCL and their potential use for personalized treatment, as well as the significant challenges they will present.